Investors in Humacyte, Inc. have filed a class action lawsuit alleging securities fraud against the company. The suit claims that Humacyte concealed critical manufacturing deficiencies, leading to investor losses. Affected shareholders have until January 17, 2025, to seek lead plaintiff status.